{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:07:14Z","timestamp":1789675634335,"version":"4.0.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Transarterial radioembolization (TARE) has emerged as a promising therapeutic approach for unresectable intrahepatic cholangiocarcinoma (ICCA). We updated our previous meta-analysis with meta-regression to explore the efficacy of TARE in the context of ICCA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched PubMed and Scopus for studies published up to September 1, 2023. The primary outcome was overall survival. Secondary outcomes were tumor overall response rate, severe adverse events, and downstaging to surgery. Meta-analysis employed a random-effects model, and meta-regression was utilized to explore sources of heterogeneity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 27 studies, involving 1365 patients. Pooled survival estimates at 1, 2, and 3\u00a0years were 52.6%, 27%, and 16.8%, respectively. Meta-regression revealed that the proportion of patients na\u00efve to treatment was the only pre-TARE predictor of survival (1-, 2-, and 3-year survival of 70%, 45%, and 36% for treatment-na\u00efve patients, mean survival 19.7\u00a0months vs. 44%, 18%, and 7% for non-na\u00efve patients, mean survival 12.2\u00a0months). Overall response according to RECIST 1.1 and mRECIST was 19.6% and 67%, respectively. Effective downstaging to surgery was possible in varying rates (3\u201354%); the mean survival in these patients was 34.8\u00a0months (1-, 2-, and 3-year survival of 100%, 87%, and 64%). About 45.7% of patients experienced adverse events, but only 5.9% were severe.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study benchmarked the survival rates of patients undergoing TARE for unresectable ICCA and showed that this is a valid option in these patients, especially if na\u00efve to previous treatments. Downstaging to surgery is feasible in selected patients with promising results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00270-024-03825-7","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T18:01:55Z","timestamp":1724695315000},"page":"1313-1324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: An Updated Meta-analysis and Meta-regression"],"prefix":"10.1007","volume":"47","author":[{"given":"Maria Adriana","family":"Cocozza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2905-1146","authenticated-orcid":false,"given":"Elton","family":"Dajti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Braccischi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Modestino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cucchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Barbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mosconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"3825_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107064","author":"M Qurashi","year":"2023","unstructured":"Qurashi M, Vithayathil M, Khan SA. Epidemiology of cholangiocarcinoma. Eur J Surg Oncol. 2023. https:\/\/doi.org\/10.1016\/j.ejso.2023.107064.","journal-title":"Eur J Surg Oncol"},{"key":"3825_CR2","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","volume":"77","author":"M Vithayathil","year":"2022","unstructured":"Vithayathil M, Khan SA. Current epidemiology of cholangiocarcinoma in Western countries. J Hepatol. 2022;77:1690\u20138.","journal-title":"J Hepatol"},{"key":"3825_CR3","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1002\/cncr.29619","volume":"121","author":"G Spolverato","year":"2015","unstructured":"Spolverato G, Vitale A, Cucchetti A, Popescu I, Marques HP, Aldrighetti L, et al. Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? Cancer. 2015;121:3998\u20134006.","journal-title":"Cancer"},{"key":"3825_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2478\/raon-2020-0045","volume":"54","author":"I Bartolini","year":"2020","unstructured":"Bartolini I, Risaliti M, Fortuna L, Agostini C, Ringressi MN, Taddei A, et al. Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments. Radiol Oncol. 2020;54:263\u201371.","journal-title":"Radiol Oncol"},{"key":"3825_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"3825_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/cancers14020362","volume":"14","author":"F Krenzien","year":"2022","unstructured":"Krenzien F, Nevermann N, Krombholz A, Benzing C, Haber P, Fehrenbach U, et al. Treatment of intrahepatic cholangiocarcinoma\u2014a multidisciplinary approach. Cancers. 2022;14:362.","journal-title":"Cancers"},{"key":"3825_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S, Chen L-T, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid."},{"key":"3825_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","volume":"20","author":"TF Greten","year":"2023","unstructured":"Greten TF, Schwabe R, Bardeesy N, Ma L, Goyal L, elley RK, et al. Immunology and immunotherapy of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2023;20:349\u201365.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3825_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","volume":"72","author":"RK Kelley","year":"2020","unstructured":"Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72:353\u201363.","journal-title":"J Hepatol"},{"key":"3825_CR10","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.3390\/cancers15153993","volume":"15","author":"E Kawamura","year":"2023","unstructured":"Kawamura E, Matsubara T, Kawada N. New era of immune-based therapy in intrahepatic cholangiocarcinoma. Cancers. 2023;15:3993.","journal-title":"Cancers"},{"key":"3825_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100723","volume":"5","author":"X Lu","year":"2023","unstructured":"Lu X, Green BL, Xie C, Liu C, Chen X. Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma. JHEP Rep. 2023;5: 100723.","journal-title":"JHEP Rep"},{"key":"3825_CR12","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/liv.13382","volume":"37","author":"A Cucchetti","year":"2017","unstructured":"Cucchetti A, Cappelli A, Mosconi C, Zhong J, Cescon M, Pinna AD, et al. Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: a meta-regression study. Liver Int. 2017;37:1056\u201364.","journal-title":"Liver Int"},{"key":"3825_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6:51.","journal-title":"JAMA Oncol"},{"key":"3825_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","volume":"79","author":"D Alvaro","year":"2023","unstructured":"Alvaro D, Gores GJ, Walicki J, Hassan C, Sapisochin G, Komuta M, et al. EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023;79:181\u2013208.","journal-title":"J Hepatol"},{"key":"3825_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"3825_CR16","doi-asserted-by":"publisher","first-page":"052","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet J. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:052\u201360.","journal-title":"Semin Liver Dis"},{"key":"3825_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"3825_CR18","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle\u2013Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"3825_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"3825_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"key":"3825_CR21","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"3825_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","volume":"11","author":"TB Huedo-Medina","year":"2006","unstructured":"Huedo-Medina TB, S\u00e1nchez-Meca J, Mar\u00edn-Mart\u00ednez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11:193\u2013206.","journal-title":"Psychol Methods"},{"key":"3825_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"3825_CR24","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1245\/s10434-009-0777-x","volume":"17","author":"A Saxena","year":"2010","unstructured":"Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. 2010;17:484\u201391.","journal-title":"Ann Surg Oncol"},{"key":"3825_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00270-011-0142-x","volume":"35","author":"R-T Hoffmann","year":"2012","unstructured":"Hoffmann R-T, Paprottka PM, Sch\u00f6n A, Bamberg F, Haug A, D\u00fcrr E-M, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012;35:105\u201316.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3825_CR26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s00270-012-0463-4","volume":"36","author":"S Rafi","year":"2013","unstructured":"Rafi S, Piduru SM, El-Rayes B, Kauh JS, Kooby DA, Sarmiento JM, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol. 2013;36:440\u20138.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3825_CR27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jvir.2013.10.056","volume":"25","author":"JC Camacho","year":"2014","unstructured":"Camacho JC, Kokabi N, Xing M, Prajapati HJ, El-Rayes B, Kim HS. Modified response evaluation criteria in solid tumors and european association for the study of the liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol. 2014;25:256\u201365.","journal-title":"J Vasc Interv Radiol"},{"key":"3825_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.nucmedbio.2014.08.011","volume":"42","author":"L Filippi","year":"2015","unstructured":"Filippi L, Pelle G, Cianni R, Scopinaro F, Bagni O. Change in total lesion glycolysis and clinical outcome after 90Y radioembolization in intrahepatic cholangiocarcinoma. Nucl Med Biol. 2015;42:59\u201364.","journal-title":"Nucl Med Biol"},{"key":"3825_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12149-015-1026-y","volume":"30","author":"C Soydal","year":"2016","unstructured":"Soydal C, Kucuk ON, Bilgic S, Ibis E. Radioembolization with 90Y resin microspheres for intrahepatic cholangiocellular carcinoma: prognostic factors. Ann Nucl Med. 2016;30:29\u201334.","journal-title":"Ann Nucl Med"},{"key":"3825_CR30","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.amjsurg.2017.11.022","volume":"215","author":"TM Shaker","year":"2018","unstructured":"Shaker TM, Chung C, Varma MK, Doherty MG, Wolf AM, Chung MH, et al. Is there a role for Ytrrium-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma? Am J Surg. 2018;215:467\u201370.","journal-title":"Am J Surg"},{"key":"3825_CR31","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s00270-017-1871-2","volume":"41","author":"P Reimer","year":"2018","unstructured":"Reimer P, Virarkar MK, Binnenhei M, Justinger M, Sch\u00f6n MR, Tatsch K. Prognostic factors in overall survival of patients with unresectable intrahepatic cholangiocarcinoma treated by means of yttrium-90 radioembolization: results in therapy-na\u00efve patients. Cardiovasc Intervent Radiol. 2018;41:744\u201352.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3825_CR32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00259-018-4199-5","volume":"46","author":"H Bourien","year":"2019","unstructured":"Bourien H, Palard X, Rolland Y, Le Du F, Beuzit L, Uguen T, et al. Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. Eur J Nucl Med Mol Imaging. 2019;46:669\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3825_CR33","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jvir.2018.04.001","volume":"29","author":"A Gangi","year":"2018","unstructured":"Gangi A, Shah J, Hatfield N, Smith J, Sweeney J, Choi J, et al. Intrahepatic cholangiocarcinoma treated with transarterial yttrium-90 glass microsphere radioembolization: results of a single institution retrospective study. J Vasc Interv Radiol. 2018;29:1101\u20138.","journal-title":"J Vasc Interv Radiol"},{"key":"3825_CR34","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1007\/s00259-019-04427-z","volume":"46","author":"H Levillain","year":"2019","unstructured":"Levillain H, Duran Derijckere I, Ameye L, Guiot T, Braat A, Meyer C, et al. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. Eur J Nucl Med Mol Imaging. 2019;46:2270\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3825_CR35","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jvir.2019.03.018","volume":"30","author":"J White","year":"2019","unstructured":"White J, Carolan-Rees G, Dale M, Patrick HE, See TC, Bell JK, et al. Yttrium-90 transarterial radioembolization for chemotherapy-refractory intrahepatic cholangiocarcinoma: a prospective. Obs Study J Vasc Interv Radiol. 2019;30:1185\u201392.","journal-title":"Obs Study J Vasc Interv Radiol"},{"key":"3825_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/jcm9010056","volume":"9","author":"M K\u00f6hler","year":"2019","unstructured":"K\u00f6hler M, Harders F, Loh\u00f6fer F, Paprottka PM, Schaarschmidt BM, Theysohn J, et al. Prognostic factors for overall survival in advanced intrahepatic cholangiocarcinoma treated with yttrium-90 radioembolization. J Clin Med. 2019;9:56.","journal-title":"J Clin Med"},{"key":"3825_CR37","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00270-020-02569-4","volume":"43","author":"I Bargellini","year":"2020","unstructured":"Bargellini I, Mosconi C, Pizzi G, Lorenzoni G, Vivaldi C, Cappelli A, et al. Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study. Cardiovasc Intervent Radiol. 2020;43:1305\u201314.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3825_CR38","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jvir.2020.02.008","volume":"31","author":"S Buettner","year":"2020","unstructured":"Buettner S, Braat AJAT, Margonis GA, Brown DB, Taylor KB, Borgmann AJ, et al. Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: a multicenter retrospective analysis. J Vasc Interv Radiol. 2020;31:1035-1043.e2.","journal-title":"J Vasc Interv Radiol"},{"key":"3825_CR39","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.18632\/oncotarget.28060","volume":"12","author":"R Paz-Fumagalli","year":"2021","unstructured":"Paz-Fumagalli R, Core J, Padula C, Montazeri S, McKinney J, Frey G, et al. Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma. Oncotarget. 2021;12:2075\u201388.","journal-title":"Oncotarget"},{"key":"3825_CR40","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jvir.2021.08.009","volume":"32","author":"A Sarwar","year":"2021","unstructured":"Sarwar A, Ali A, Ljuboja D, Weinstein JL, Shenoy-Bhangle AS, Nasser IA, et al. Neoadjuvant yttrium-90 transarterial radioembolization with resin microspheres prescribed using the medical internal radiation dose model for intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2021;32:1560\u20138.","journal-title":"J Vasc Interv Radiol"},{"key":"3825_CR41","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1007\/s00270-021-02834-0","volume":"44","author":"B Cheng","year":"2021","unstructured":"Cheng B, Villalobos A, Sethi I, Wagstaff W, Galt J, Brandon D, et al. Determination of tumor dose response thresholds in patients with chemorefractory intrahepatic cholangiocarcinoma treated with resin and glass-based y90 radioembolization. Cardiovasc Intervent Radiol. 2021;44:1194\u2013203.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3825_CR42","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.3390\/cancers13215399","volume":"13","author":"KJ Paprottka","year":"2021","unstructured":"Paprottka KJ, Gali\u00e8 F, Ingrisch M, Geith T, Ilhan H, Todica A, et al. Outcome and safety after 103 radioembolizations with yttrium-90 resin microspheres in 73 patients with unresectable intrahepatic cholangiocarcinoma\u2014an evaluation of predictors. Cancers. 2021;13:5399.","journal-title":"Cancers"},{"key":"3825_CR43","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jceh.2022.03.008","volume":"12","author":"P Kumar","year":"2022","unstructured":"Kumar P, Mhaskar R, Kim R, Anaya D, Frakes J, Hoffe S, et al. Unresectable intrahepatic cholangiocarcinoma treated with radiation segmentectomy\/lobectomy using yttrium 90-labeled glass microspheres. J Clin Exp Hepatol. 2022;12:1259\u201363.","journal-title":"J Clin Exp Hepatol"},{"key":"3825_CR44","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.3390\/cancers14215324","volume":"14","author":"I Schatka","year":"2022","unstructured":"Schatka I, Jochens HV, Rogasch JMM, Walter-Rittel TC, Pelzer U, Benckert J, et al. Transarterial yttrium-90 radioembolization in intrahepatic cholangiocarcinoma patients: outcome assessment applying a prognostic score. Cancers. 2022;14:5324.","journal-title":"Cancers"},{"key":"3825_CR45","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jvir.2022.10.042","volume":"34","author":"TJ Robinson","year":"2023","unstructured":"Robinson TJ, Du L, Matsuoka L, Sze DY, Kennedy AS, Gandhi RT, et al. Survival and toxicities after yttrium-90 transarterial radioembolization of cholangiocarcinoma in the RESiN registry. J Vasc Interv Radiol. 2023;34:694-701.e3.","journal-title":"J Vasc Interv Radiol"},{"key":"3825_CR46","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00270-022-03183-2","volume":"45","author":"AN Gupta","year":"2022","unstructured":"Gupta AN, Gordon AC, Gabr A, Kalyan A, Kircher SM, Mahalingam D, et al. Yttrium-90 radioembolization of unresectable intrahepatic cholangiocarcinoma: long-term follow-up for a 136-patient cohort. Cardiovasc Intervent Radiol. 2022;45:1117\u201328.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3825_CR47","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jvir.2022.12.017","volume":"34","author":"O Ahmed","year":"2023","unstructured":"Ahmed O, Yu Q, Patel M, Hwang G, Pillai A, Liao C, et al. Yttrium-90 radioembolization and concomitant systemic gemcitabine, cisplatin, and capecitabine as the first-line therapy for locally advanced intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2023;34:702\u20139.","journal-title":"J Vasc Interv Radiol"},{"key":"3825_CR48","doi-asserted-by":"publisher","first-page":"153303382311556","DOI":"10.1177\/15330338231155690","volume":"22","author":"C Mosconi","year":"2023","unstructured":"Mosconi C, Cacioppa LM, Cappelli A, Gramenzi AG, Vara G, Modestino F, et al. Update of the Bologna experience in radioembolization of Intrahepatic cholangiocarcinoma. Technol Cancer Res Treat. 2023;22:153303382311556.","journal-title":"Technol Cancer Res Treat"},{"key":"3825_CR49","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2967\/jnumed.122.264598","volume":"64","author":"BM Schaarschmidt","year":"2023","unstructured":"Schaarschmidt BM, Kloeckner R, Dertnig T, Demircioglu A, M\u00fcller L, Auer TA, et al. Real-life experience in the treatment of intrahepatic cholangiocarcinoma by 90 Y radioembolization: a multicenter retrospective study. J Nucl Med. 2023;64:529\u201335.","journal-title":"J Nucl Med"},{"key":"3825_CR50","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/liv.15641","volume":"43","author":"M Rimini","year":"2023","unstructured":"Rimini M, Fornaro L, Lonardi S, Niger M, Lavacchi D, Pressiani T, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data. Liver Int. 2023;43:1803\u201312.","journal-title":"Liver Int"},{"key":"3825_CR51","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/RLU.0000000000000904","volume":"40","author":"J Edeline","year":"2015","unstructured":"Edeline J, Du FL, Rayar M, Rolland Y, Beuzit L, Boudjema K, et al. Glass microspheres 90Y selective internal radiation therapy and chemotherapy as first-line treatment of intrahepatic cholangiocarcinoma. Clin Nucl Med. 2015;40:851\u20135.","journal-title":"Clin Nucl Med"},{"key":"3825_CR52","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Lee K-H, Lee D-W, Yoon J, Kim T-Y, Bang J-H, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol. 2022;7:522\u201332.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3825_CR53","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00270-023-03657-x","volume":"47","author":"P Reimer","year":"2024","unstructured":"Reimer P, Vilgrain V, Arnold D, Balli T, Golfieri R, Loffroy R, et al. Factors impacting survival after transarterial radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: a combined analysis of the prospective cirt studies. Cardiovasc Intervent Radiol. 2024;47:310\u201324.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3825_CR54","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s11547-020-01240-9","volume":"126","author":"M Bozkurt","year":"2021","unstructured":"Bozkurt M, Eldem G, Bozbulut UB, Bozkurt MF, K\u0131l\u0131\u00e7kap S, Peynircio\u011flu B, et al. Factors affecting the response to Y-90 microsphere therapy in the cholangiocarcinoma patients. Radiol Med. 2021;126:323\u201333.","journal-title":"Radiol Med"},{"key":"3825_CR55","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00432-022-04485-1","volume":"149","author":"M He","year":"2023","unstructured":"He M, Jiang N, Yin X, Xu A, Mu K. Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a systematic review and pooled analysis. J Cancer Res Clin Oncol. 2023;149:531\u201340.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3825_CR56","doi-asserted-by":"publisher","first-page":"1270264","DOI":"10.3389\/fgstr.2023.1270264","volume":"2","author":"MA Cocozza","year":"2023","unstructured":"Cocozza MA, Braccischi L, De Cinque A, Bruno A, Cappelli A, Renzulli M, et al. Unresectable intrahepatic cholangiocarcinoma: TARE or TACE, which one to choose? Front Gastroenterol. 2023;2:1270264.","journal-title":"Front Gastroenterol"},{"key":"3825_CR57","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00270-021-02800-w","volume":"44","author":"C Mosconi","year":"2021","unstructured":"Mosconi C, Solaini L, Vara G, Brandi N, Cappelli A, Modestino F, et al. Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma\u2014a systemic review and meta-analysis. Cardiovasc Intervent Radiol. 2021;44:728\u201338.","journal-title":"Cardiovasc Intervent Radiol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-024-03825-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-024-03825-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-024-03825-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T20:28:46Z","timestamp":1729196926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-024-03825-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["3825"],"URL":"https:\/\/doi.org\/10.1007\/s00270-024-03825-7","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]},"assertion":[{"value":"17 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"For this type of study, informed consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"For this type of study, consent for publication is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}